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KESAN HEMODINAMIK DARIPADA  ADIPONECTIN TERHADAP  
RESEPTOR PPAR–γ DALAM  WISTAR KYOTO TIKUS DIABETES DAN  
HIPERTENSI SECARA SPONTAN 
 
 
ABSTRAK 
 
 Prevalens hipertensi dan diabetes semakin meningkat dengan kadar yang belum 
pernah berlaku sebelum ini  di kedua-dua negara sedang membangun dan juga di negara 
maju. Adiponectin, yang merupakan suatu adipokin, adalah hormon protein yang 
menyederhana tindakannya dengan merangsang pelepasan nitrik oksida (NO) daripada  
endotelium vascular dan menyebabkan vasodilasi. PPAR-γ merupakan ahli reseptor 
diaktif proliferator peroksisom, yang merupakan  pengawal atur positif bagi ekspresi gen 
adiponectin. Dalam kajian ini, irbesartan digunakan sebagai agonis PPAR-γ separa, 
Sebaliknya, pioglitazon  bertindak sebagai ligan penuh bagi  PPAR-γ dan menyebabkan 
peningkatan kepekatan adiponectin plasma. Kajian ini mengkaji antihipertensi, 
antidiabetes, potensi antioksidan dan hemodinamik renal adiponectin dengan agonis 
PPAR-γ dalam model diabetes dan bukan diabetes daripada tikus hipertensi. Di samping 
itu, kesan adiponectin dan gabungan rawatan daripada adiponectin dengan agomis PPAR-
γ separa atau penuh pada α1-adrenoceptor menyebabkan perubahan vaskular renal dan 
sistemik daripada tikus hipertensi dan  normotensi diabetes dan bukan diabetes turut 
dikaji. Diabetes jenis I diaruh menggunakan suntikan / injeksi  intraperitoneal tunggal 
daripada streptozotosin pada  dos 40 mg/kg berat badan yang dilarutkan dalam penampan 
natrium sitrat (pH 4.5). Satu set tikus normotensi (WKY) dan hipertensi (SHR) diberikan 
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irbesartan, pioglitazone, adiponectin dan gabungan adiponectin dengan sama ada  
irbesartan atau pioglitazon. Sementara itu, satu set lain yang tediri daripada tikus 
normotensi bukan diabetes  (WKY) dan tikus hipertensi (SHR) diberikan pola atau corak 
rawatan yang sama. Tekanan darah (BP) dan parameter metabolisme diukur pada tikus. 
Di samping itu, kelajuan gelombang nadi, perfusi darah kortikal renal, adiponectin 
plasma, profil cecair dan elektrolit juga diukur semasa dan pada akhir kajian.  
Selanjutnya, tikus diberi natrium pentobarbiton beranestetik dan dikurangkan min 
tekanan arteri dan aliran darah kortikal renal diaruh melalui pemberian secara sistemik 
dan intrarenal daripada noradrenalin, fenilefrin, metoksamin  dan angiotensin II (Ang II). 
Data, mean±SEM tertakluk pada ANOVA dengan signifikan pada P<0.05. Diabetes SHR 
mempunyai BP yang lebih tinggi, adiponectin plasma yang rendah, ketidakfungsian renal 
ditunjukkan dengan peningkatan kreatinin plasma, klearans kreatinin, kumuhan /ekskresi 
natrium dalam bentuk pecahan dan mutlak.  Rawatan dengan adiponectin sahaja dan 
gabungan adiponectin dengan agonis PPAR-γ separa atau lengkap didapati 
mengurangkan BP, mengurangkan respons vaskular renal dan sistemik pada agonis α1-
adrenergic dan Ang II, memperbaiki stres oksidatif dan meningkatkan hemodinamik 
renal dan fungsi kumuhan,  justeru, ia  menberikan suatu interaksi kompleks di antara 
subjenis α1-adrenoceptor,  reseptor ANG II dan adiponectin reseptor. Gabungan terapi 
adiponectin dengan pioglitazone menggariskan peranan perlindungan reno daripada 
adiponectin . Oleh itu, darjah sinergisme wujud di antara  adiponectin dan agonis PPAR-γ 
lengkap (pioglitazone). 
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HAEMODYNAMIC EFFECTS OF ADIPONECTIN ON PPAR–γ RECEPTORS IN 
DIABETIC AND NON-DIABETIC WISTAR KYOTO AND SPONTANEOUSLY 
HYPERTENSIVE RATS 
 
 
ABSTRACT 
 
           The prevalence of hypertension and diabetes is mounting with unprecedented 
degree in both developing and advanced countries. Reduced plasma adiponectin 
concentrations have been found in hypertension and diabetes. Adiponectin, an adipokine, 
is a protein hormone which mediates its action by stimulating nitric oxide (NO) release 
from the vascular endothelium thereby causing vasodilation. PPAR-γ is a member of 
Peroxisome proliferator activated receptor, which is positive regulator of adiponectin 
gene expression. In this study irbesartan has been used as partial PPAR-γ agonist, by 
contrast, pioglitazone acts as full ligand for PPAR-γ, which causes increases in 
adiponectin plasma concentration. This study investigated the antihypertensive, anti-
diabetic, antioxidant potential and renal haemodynamics of adiponectin with PPAR-γ 
agonists in diabetic and non-diabetic model of rats. Besides, the effect of adiponectin and 
combined treatment of adiponectin with partial or full PPAR-γ agonists on the α1-
adrenoceptor subtypes responsiveness in systemic and renal vasculature alteration of 
diabetic and non-diabetic normotensive and hypertensive rats was explored. Type 1 
diabetes was induced using a single intra-peritoneal injection of streptozotocin at a dose 
of 40 mg/kg body weight, dissolved in sodium citrate buffer (pH 4.5). One set of diabetic 
normotensive (WKY) and hypertensive (SHR) rats received irbesartan, pioglitazone, 
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adiponectin and combination of adiponectin with either irbesartan or pioglitazone, while 
the other set of non-diabetic WKY and SHRs received the same pattern of treatment. 
Blood pressure (B.P) and metabolic parameters were measured in conscious rats. In 
addition pulse wave velocity, renal cortical blood perfusion, plasma adiponectin, lipid 
profile and electrolytes were also measured during and at the end of study. Moreover, rats 
were anaesthetized with sodium pentobarbitone and reductions in mean arterial pressure 
and renal cortical blood flow induced by systemic and intra-renal administration of 
noradrenaline, phenylephrine, methoxamine and angiotensin II (Ang II) were determined. 
Data, mean±SEM were subjected to ANOVA with significance at P<0.05. Diabetic 
SHRs had higher B.P, low plasma adiponectin, renal dysfunction marked by increased 
plasma creatinine, creatinine clearance, absolute and fractional sodium excretion. 
Treatment with adiponectin alone and combination of adiponectin with either partial or 
full PPAR-γ agonists reduced B.P, blunted systemic and renal vascular response to α1-
adrenergic agonists and Ang II, ameliorate oxidative stress and improved renal 
haemodynamics and excretory functions, thus signify a complex interaction between α1-
adrenoceptor subtypes, Ang II and adiponectin receptors. Moreover, combined 
adiponectin with pioglitazone underlie a reno-protective role of adiponectin, and signifies 
a degree of synergism exist between adiponectin and full PPAR-γ agonist (pioglitazone) 
treatment.   
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CHAPTER 1: INTRODUCTION 
1.1  Kidney 
1.1.1  Anatomy of kidney 
In human beings, there is a pair of kidneys, one on each side of spine and located in the 
abdominal cavity called the retroperitoneal space. The exact location of kidneys in human 
beings is approximately at the vertebral level T12 to L3 (Walter and Boron, 2004). Each 
adult kidney weighs between 125 and 170 grams in males and between 115 and 
155 grams in females. The kidney is approximately 11–14 cm in length, 6 cm wide and 
4 cm thick. The left kidney is typically slightly larger than the right (Glodny et al. 2009). 
 Macroscopically each kidney has been described as a bean-shaped organ having 
both concave and convex surfaces. On the concave surface i.e., the medial side, there is a 
depression called hilum, at which the renal artery and nerve enters the organ, whereas the 
renal vein and ureter leaves the kidney (Marieb and Hoehn, 2007). In a cross section of 
the kidney, two major regions can be identified. The outer or superficial reddish brown 
region, which is granular in appearance, called cortex and inner or deep darker brown, 
appears striated is known as medulla. Nephrons, the urine-producing functional unit of 
the kidney, span the cortex and medulla (Shier, 2003). There are about 20 million 
nephrons in each kidney. The initial filtering portion of a nephron is made of glomerulus 
and Bowmans capsule collectively called renal corpuscle, located in the cortex, which is 
followed by renal tubule that passes from cortex deep into the medullary pyramids 
(Walter and Boron, 2004).  The renal tubules consist of proximal convoluted tubule,   
loop of Henle and distal convoluted tubule. Kidneys receive blood from the respective 
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renal artery, left and right, which branches directly from the abdominal aorta.  Each  renal  
artery  branches into segmental arteries, dividing further into interlobar  arteries  that  
penetrate the renal capsule and extend through the renal columns between  the  renal  
pyramids. Each arcuate artery supplies several interlobular arteries that feed into the 
afferent arterioles that supply the glomeruli (Walter and Boron, 2004). After filtration, 
the blood moves through a small network of venules that converge into interlobular veins. 
As with the arteriole distribution, the  veins  follow  the same pattern,  the  interlobular  
veins  provide  blood to  arcuate veins  then  back  to  interlobar  veins that unite  to  form  
the  renal vein that exits at the hilus of the kidney. Renal veins return the blood to inferior 
vena cava (Vander, 1995, Applegate, 2000, and Meyer et al. 2004). 
 The kidney and nervous system communicate via the renal plexus, whose fibres’ 
course along the renal arteries to reach the kidney. Input from the SNS triggers 
vasoconstriction in the kidney, thereby reducing renal blood flow. Interestingly kidney is 
devoid of input from the parasympathetic nervous system (Bard et al. 2003).  
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Figure 1.1: Gross anatomy of kidney  
(Adapted from 2009 WebMD, LLC, Anatomy of the Human Body). 
 
1.1.2  Physiology of Kidney 
  Kidneys contribute in whole-body homeostasis through the excretion of waste 
products of metabolism like urea and uric acid, regulation of acid base balance, 
electrolyte concentrations and extracellular fluid volume. Kidneys are also involved in 
the reabsorption of important nutrients like glucose and amino acids. The production of 
various hormones like erythropoietin and activation of vitamin-D also come under the 
functions of kidneys (Dantzler, 1989).  Most  of  kidney's functions are completed by the 
simple  mechanisms  of  filtration,  reabsorption  and secretion  that  take  place within  
the  nephron.  Filtration occurs at the renal corpuscle. It is the process by which cells and 
large proteins are filtered from the blood to make the glomerular filtrate that eventually 
becomes urine. The kidney produces about 180 liters of ultra filtrate per day, while 
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reabsorbing a large percentage, allowing for the production of only approximately 2 liters 
of urine.  Reabsorption is the transport of molecules from this ultra filtrate and into the 
blood. On the other hand, secretion is the reverse process, in which molecules are 
transported in the opposite direction, from the blood into the urine (Guyton, 1991b). One 
of the most vital functions that the normal kidneys perform is the long-term regulation of 
blood pressure. This regulation occurs through preservation of the extracellular 
fluid compartment, the size that depends on plasma sodium concentration through the 
activation of renin angiotensin-aldosterone system (Hall and Guyton, 2011). Kidneys 
work in conjunction with cardiovascular, endocrine and nervous system in order to 
maintain the blood pressure (Germann et al. 2005). 
1.2  Cardiovascular system 
1.2.1  Anatomy of cardiovascular system 
 The cardiovascular system distributes the blood and consists of the heart, blood 
and blood vessels. One of the essential components of cardiovascular system is the closed 
circulatory system that permits blood and lymph circulation in order to transport  
nutrients and waste products to and from cells in body (Dorland, 2011). In humans, the 
circulatory system includes the pulmonary circulation and systemic circulation. 
Pulmonary circulation is a loop through the lungs where blood gets oxygenated, whereas 
the systemic circulation provides oxygenated blood to the rest of the body (Guyton and 
Hall, 2006). The deoxygenated blood is brought back to the right atrium via the superior 
and inferior vena cava and follow through the tricuspid valve to the right ventricle, from 
where it is pumped through the pulmonary artery to lungs. Gaseous exchange occurs in 
the lungs and pulmonary vein returns the oxygenated blood to left atrium. Conversely, 
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systemic circulation transports oxygen rich blood away from the heart to the body except 
lungs from the left ventricle through aorta and bring back the oxygen-depleted blood 
back to the heart (Guyton and Hall, 2006).  
1.2.2  Heart and blood vessels 
The human heart is composed of cardiac muscle, which is an involuntary striated muscle 
tissue found only in this organ, and connective tissue. On the average human heart, beats  
72 times per minute, roughly beats 2.5 billion times during an average sixty-five years of 
lifespan, and weighs approximately 300 to 350 grams (Kumar et al. 2005). The heart is 
muscular conical organ that lies between the lungs in the middle mediastinum and is 
enclosed in the pericardium. Heart is placed obliquely anterior to the vertebral column 
and behind the body of sternum so that 1/3 of it lies to the right and 2/3 lies to the left of 
median plane. It is enclosed in a double-walled sac called the pericardium. The 
superficial part of this sac is called the fibrous pericardium (Gavaghan, 1998). The outer 
wall of the human heart is composed of three layers. The outer layer is called the 
epicardium, or visceral pericardium since it is also the inner wall of the pericardium. The 
middle layer is called the myocardium and is composed of muscle that contracts. The 
inner layer is called the endocardium and is in contact with the blood that the heart pumps 
and it merges with the inner lining (endothelium) of blood vessels and covers the heart 
valves (Iles and Docherty, 2011). 
 The blood vessels refer to the closed system of tubes that transport blood to all 
parts of the body and back to the heart. The blood vessels consist of arteries, arterioles, 
capillaries, venules, and veins. The actual exchange of oxygen, carbon dioxide and waste 
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matter between the blood and the tissue fluid occurs in microscopically small vessels, 
called capillaries (Hall, 2010). Structurally the wall of arteries composed of three layers 
viz; tunica intima, tunica media and tunica adventitia. Tunica intima consists of an inner 
surface of smooth endothelium covered by a layer of elastic tissues. The tunica media is 
thicker in arteries and consists of smooth muscle cells mixed with elastic fibers. Tunica 
media of larger vessels is primarily composed of elastic fibers. Tunica adventitia of blood 
vessels is composed of collagenous and elastic fibres (Derrickson and Tortora, 2006, 
Human cardiovascular system, 2013). Progressive thinning of the vessel wall and a 
decrease in the size of the lumen results in the formation of arterioles that provides the 
most of the peripheral resistance (Tobian et al. 1961). 
1.2.3  Physiology of Cardiovascular system 
The heart acts as a functional syncytium and is divided into the right side and left side 
heart. Function of the right side of heart is to collect de-oxygenated blood, in the right 
atrium, from the body via superior and inferior vena cava and pump it to right ventricle, 
through the tricuspid valve into the lungs termed as pulmonary circulation. In the lungs 
there is oxygenation of blood through the passive process of diffusion. The left sided 
heart collects oxygenated blood from the lungs into the left atrium. From the left atrium 
the blood moves to the left ventricle, through the bicuspid valve, which pumps it out to 
the body via the aorta. On both sides, the lower ventricles are thicker and stronger than 
the upper atria. The muscle wall surrounding the left ventricle is thicker than the wall 
surrounding the right ventricle due to the higher force needed to pump the blood through 
the systemic circulation (Scott, 1986). The one complete beat of the heart that is one 
systole followed by one diastole is referred as one cardiac cycle. The duration of one 
7 
 
cardiac cycle in human beings is 0.8 seconds. Systole lasts for 0.3 seconds and diastole 
lasts for 0.5 seconds (Guyton and Hall, 2006). The heart is responsible for pumping blood 
throughout the blood vessels by repeated, rhythmic contractions and acts as a functional 
syncytium. Cardiac contractions are managed by specialized and self-excitatory 
conductive system of the heart. This conducting system consists of sinoatrial node or S-A 
node, in which the normal rhythmic impulse is generated; internodal pathway; A-V node; 
A-V bundle and right and left bundles of Purkinje fibers. Automacity is the process that 
can cause automatic rhythmical contractions and is best expressed in S-A node that is 
also known as pacemaker of the heart. Once a cardiac impulse is generated at the S-A 
node, it subsequently spread to all parts of heart through the conducting system resulting 
in rhythmic contractions and ventricles provide the major source of power for moving  
blood in the vascular system (Hall & Guyton, 2011). The cardiovascular system serve the 
needs of the tissue including transport of nutrients to tissue, transport of waste products 
away from tissues, hormones transport , maintenance of pH, thermoregulation, providing 
the necessary cardiac output and arterial pressure, preservation of fluid balance and to 
maintain homeostasis. The cardiovascular system works in concurrence with other body 
systems such as nervous, endocrine, renal and respiratory to maintain a suitable and 
steady environment. 
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Figure 1.2 Gross anatomy of cardiovascular system of heart  
(Adapted from Pearson Education, Inc. Publishing, 2013). 
 
1.3  Hypertension 
Hypertension is a common worldwide health problem and about 40% of individuals had 
been diagnosed with this chronic illness in year 2008 (World Health, 2013). According to 
the Joint National Committee 7 (JNC 7), hypertension is defined as physician office 
systolic BP level of ≥ 140 mmHg and diastolic BP of ≥ 90 mmHg. The gray area between 
systolic BP of 120-139 mmHg and diastolic BP of 80-89 mmHg is defined as 
“prehypertension” (Chobanian et al. 2003). 
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1.3.1  Blood Pressure 
Blood pressure is defined as the pressure exerted by the blood against any unit area of 
vessel wall (Guyton, 1991a). Blood pressure is the resultant of the activity of heart and 
blood vessels. Simply, blood pressure is equal to cardiac output multiplied by total 
peripheral resistance. The normal blood pressure ranges are systolic blood pressure 90-
119 mmHg and diastolic blood pressure 60-79 mmHg (Chobanian et al. 2003). Many 
interrelated physiological mechanisms are involved in maintaining the blood pressure 
including sympathetic and parasympathetic nerves, baroreceptors, circulatory hormones 
and local auto-regulatory mechanisms. Derangement in these factors contributes to the 
elevation of blood pressure (Beevers et al. 2001).  
                       Table 1.1: Classification of blood pressure 
Classification Systolic BP (mmHg) Diastolic BP (mmHg) 
Normal <120 And <80 
Pre-hypertension 120-139 Or 80-89 
Stage 1 hypertension 140-159 Or 90-99 
Stage 2 hypertension > 160 > 100 
BP = blood pressure (Human cardiovascular system), Data from National heart, lung and blood. 
Institute: www. britannica.com/ hypertension (accessed November, 2013). 
1.3.2  Primary and secondary hypertension 
Hypertension is divided into primary or essential and secondary hypertension. Primary 
hypertension is where there is rise of blood pressure due to unknown cause with a 
subsequent increased risk of cerebral, cardiac and renal complications (Messerli et al., 
2007). Essential hypertension accounts for 90-95% cases of hypertension. The term 
secondary hypertension refers to remaining 5-10% cases of hypertension of known 
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origin. Primary hypertension, where there is no identifiable cause, is often a result of 
complex interactions between multiple environmental and genetic factors. On the other 
hand, identifiable causes of secondary hypertension include genetic syndromes, renal 
disease, renal vascular hypertension, Cushing syndrome, primary hyperaldosteronism, 
pregnancy, pheochromocytoma,  hypercalcemia and medications (McPhee et al. 2010). 
1.3.3  Pathophysiology of hypertension 
Many pathophysiological mechanisms are involved in the genesis and maintenance of 
hypertension. However, extensive experimental and clinical data supports the view that 
impaired renal functions play a primary and vital role in the pathogenesis of hypertension 
as proposed by Guyton and Hall (Hall and Guyton, 2011). Pathophysiology is quite 
complex and multi-factorial, all these factors interact with each other through complex 
mechanisms that results in an increase of blood pressure, and related target organs 
damage (Feinleib et al. 1977, Longini et al. 1984). However, it has been suggested that 
the genetic causes of hypertension is uncommon in general hypertensive population. 
Moreover, the genetic predisposition can be expressed fully by the interaction of 
environmental and demographic factors (Oparil et al. 2003). Likewise, hypertension and 
type II diabetes mellitus coexist (Haffner et al. 1998). Similarly, metabolic syndrome also 
has been proposed in the pathogenesis of hypertension (Epstein et al. 1996).  It has been 
proposed that over activity of SNS contributes to the development and maintenance of 
hypertension through increased cardiac output, increased vascular resistance and 
abnormal water retention (Mark, 1996). It has been reported that the vascular reactivity of  
hypertensive patients is greater as they exhibit greater vasoconstrictor responses to 
infused noradrenaline than normotensive persons (Ziegler et al. 1991).  
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Renal vasoconstriction, renal ischemia, local generation of reactive oxygen species and 
over production and activation of local angiotensin II act as stimului for renal  
vasculopathy and hemodynamic effects leading to hypertension (Sealey et al. 1988). 
Vascular remodeling resulting in an increased vascular peripheral resistance is another 
feature of hypertension. Such that alteration in structure and functions of small arteries 
contribute to the elevation of blood pressure (Mulvany and Aalkjær, 1990). Since the 
discovery of renin-angiotensin-aldosterone system (RAAS), its role in the pathogenesis 
of hypertension had been extensively studied and was found to be the key factor in the 
genesis and maintenance of hypertension. RAAS contributes in the elevation of blood 
pressure through multiple mechanisms including vasoconstriction of resistance vessels, 
release of aldosterone, renal sodium reabsorption, release of anti-diuretic hormone and 
augmenting of central sympathetic outflow. Angiotensin II (Ang II) has also been 
implicated in cardiac and vascular cell hypertrophy and hyperplasia through the 
activation of angiotensin type I receptors and by stimulating the release of growth factors 
and cytokines (McConnaughey et al. 1999). Similarly, aldosterone excess has been now 
considered as common contributing factor in hypertension (Lijnen and Petrov, 2000). 
Moreover, arterial stiffness and high levels of circulatory endothelin have also been 
proposed in the development of hypertension (Ergul et al. 1996).  
 The concept of oxidative stress and endothelial dysfunction contributing to the 
pathogenesis of hypertension has gained interest in recent years. Angiotensin II-induced 
activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase results in 
an increased production of oxidant superoxide anions (O2•¯). Increased O2•¯ production 
results in oxidative inactivation of nitric oxide (NO) and the resultant decreased bio-
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availability of NO provides another mechanism of increased vasoconstriction and 
hypertension (Rajagopalan et al. 1996). Adipose tissue releases leptin, angiotensinogen 
and oxidized fatty acids to stimulate adrenal release of aldosterone via activation of the 
classic RAAS, as well as a non-classical pathway mediated by oxidized fatty acids. 
Leptin stimulates the central SNS, which in turn leads to renin release from the kidney. 
Activation of RAAS in other tissues contributes to renal and vascular dysfunction. 
Increased adipose tissue can lead to obstructive sleep apnoea (OSA), which can be treated 
by therapeutic weight loss or application of continuous positive airway pressure (cPAP). 
OSA leads to activation of the sympathetic nervous system (SNS), which activates RAAS 
in the kidney. Increased aldosterone can be reduced with mineralocorticoid receptor 
antagonists, (Figure 1.3).   
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Figure 1.3: Pathophysiological mechanisms of hypertension 
(Adapted from DeMarco et al. 2014). 
Cpap: continuous positive airway pressure; OSA: obstructive sleep apnoea, 
RAAS: renin–angiotensin–aldosterone system; SNS: sympathetic nervous system, 
ARB: angiotensin receptor blocker, Ang II: angiotensin II. 
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1.4  Diabetes 
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, 
both in the US and worldwide. The world wide prevalence of diabetes in year 2000 was 
approximately 2.8% and is estimated to grow to 4.4% by the year 2030, that will lead to a 
rise in the number of diabetic patients from 171 million in year 2000 to 350 million in 
year 2030 (Wild et al. 2004). 
 Diabetes mellitus is one of the most important public health problems prevailing 
worldwide with a leading cause of death and huge economic burden.  Until the early part 
of the 20th century, being diagnosed with diabetes used to mean certain death within few 
years due to the lack of proper therapeutic options. The revolutionary discovery of insulin 
allowed a control of this disease in terms of reduced mortality and morbidity. The 
advancement of science also enabled to undertake in-depth studies regarding the related 
intricate pathophysiology of diabetes and brought the adverse effect of this disease in 
forefront of medical and health research. The increasing prevalence and globalization of 
this disease has increased and is particularly observed in the recent decades (Kennedy 
and Zochodne, 2005).   
 Diabetes is defined as a chronic metabolic disorder that affects the metabolism of 
carbohydrates and other nutrients because of impaired insulin release and/or insulin 
resistance resulting in hyperglycemia (Tierney et al. 1996) Diabetes mellitus is classified 
into insulin dependent diabetes mellitus (IDDM) or type 1 diabetes and non-insulin 
dependent diabetes mellitus (NIDDM) or type 2 diabetes.  The type 1 diabetes is mainly 
related to insulin deficiency in which a sequel of β-cell destruction is widely implicated 
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in the pathogenesis of this type of diabetes. The type 2 diabetes may be caused due to 
either cellular insensitivity to insulin or insulin resistance and/or secretory dysfunction 
related to impaired β-cell function or the presence of non-functional β-cells. Type 1 
diabetes mellitus which is characterized by loss of the insulin-producing beta cells of the 
islets of Langerhans in the pancreas leading to a deficiency of insulin. It is either 
immune-mediated or idiopathic (Boon & Davidson, 2006). The majority of type 1 
diabetes is of the immune-mediated in nature, where the loss of beta cells is due to 
autoimmune attack mediated by T-cell (Johns Hopkins Autoimmune Disease Research 
Center, 2007). On the other hand, Type II diabetes mellitus is characterized by the 
presence of insulin resistance or reduced insulin sensitivity, and with relatively reduced 
insulin secretion. This defective response of body tissues to circulating insulin involves 
insulin receptor in cell membranes (Rother, 2007). The exact cause and mechanism is not 
fully understood in type II diabetes mellitus. Certain risk factors are associated with 
increased incidence of diabetes such as obesity, as 55% of patient diagnosed with type 2 
diabetes mellitus have central obesity. Other factors include ageing, increasing body mass 
and decrease demands of physical activity and family history (Kopelman, 2000). 
Genetics are strongly linked with both types of diabetes mellitus (Walley et al. 2006). 
The hyperglycemia due to poor glycemic control is common in overt diabetes and is 
associated with dysfunctions of different organs, particularly kidney, nerves, eye, heart 
and blood vessels. (Cooper et al. 2001). 
1.4.1  Diabetes and hypertension 
Hypertension and diabetes often coexist. Diabetics have increased prevalence of 
developing the hypertension. One prospective study (that included 12,550 adults), 
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indicates that  the  development  of  diabetes  in  hypertensive  patients is 2.5 times 
greater as compared to normotensive subjects (National High Blood Pressure Education 
Program Working Group, 1994). Similarly, previous data suggests that there is increased 
prevalence of diabetes in hypertension and approximately 20% of hypertensives have 
coexisting diabetes (Contreras et al. 2000).  Moreover,  both  diseases  serve  to  induce  
and  as  well  as  exacerbate  each  other (Sowers and Epstein, 1995). Both hypertension 
and diabetes predispose to the development of cardiovascular disease (CVD) and renal 
disease as their major complications (Sowers, 2004). The co-existence of hypertension 
and diabetes in patients increases the risks of cardiovascular diseases by 75% (Adler et al. 
2000). Diabetes mellitus & systemic hypertension promote the process of atherosclerosis, 
and their combination further increases this risk (Fuller, 1985). 
1.4.2  Complications of diabetes in hypertension and oxidative stress  
Hypertension and diabetes are associated with marked abnormalities of cardiovascular 
structure and functions. Hypertension and diabetes both can induce coronary heart 
disease, infarction, cerebrovascular accidents, nephropathy and retinopathy and 
peripheral vascular diseases (Bakris et al. 2000). Diabetes is commonly associated with 
both micro- and macro-vascular complications. These vascular complications are mainly 
accelerated in context of systemic hypertension. The underlying molecular mechanisms 
responsible for diabetic vascular complications are being elucidated.  A large body of 
research is examining this topic and it appears that in case of diabetes, both metabolic and 
hemodynamic factors interact to stimulate the expression of cytokines and growth factors 
in the various vascular trees and contribute in the genesis of these complications.  
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Diabetes provides a distinct model of chronic vascular disease in which altered glycemic 
status of the body results in multiple organ dysfunctions. These diabetes-induced 
complications can divided into micro- and macro-vascular complications.  Neuropathy, 
nephropathy and retinopathy are major diabetic micro-vascular complications of diabetes. 
The macro-vascular complication of diabetes is manifested as accelerated atherosclerosis 
that predisposes the patients to premature ischemic heart disease, increased risk for 
cerebrovascular disease and for severe peripheral vascular diseases. Several factors 
including metabolic, humoral & hemodynamic factors  are believed to be involved in the 
pathogenesis of vasculopathy frequently observed in overt and poorly controlled diabetes 
(Wood et al. 1995). 
 Hypertension is a chronic medical condition and frequently remains 
asymptomatic until late in its course. It can be classified as essential (primary) and 
secondary hypertension. Essential hypertension is of unknown cause and constitutes 
about 90 to 95% of cases. Many pathophysiological factors contribute to the genesis of 
essential hypertension such as high sodium intake, inadequate dietary intake of potassium 
and calcium, increased secretion of renin, angiotensin II and aldosterone, overproduction 
of sodium-retaining hormones and vasoconstrictors, increased sympathetic activity and 
deficiencies of vasodilators (Wood et al. 1995). 
 In hypertension, production of cardiac and vascular ROS is increased. Increase in 
vascular oxidative stress has been observed in different models of experimental 
hypertension like angiotensin-II induced hypertension, Dahl salt-sensitive hypertension, 
obesity-associated hypertension, and SHR. Antioxidants and SOD mimetic decreased 
blood pressure and prevented the development of hypertension in animal models of 
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hypertension (Park et al. 2002). These  beneficial  effects  point  towards  the  role  of  
ROS  in  the  development  of hypertension  and vascular complications.  In hypertension, 
antioxidants may improve endothelial function, regress vascular remodeling and reduce 
vascular inflammation. 
 Endothelial dysfunction is considered as the first step in the pathogenesis of micro 
and macro vascular complications of both diseases. Endothelium, the inner lining of 
blood vessels, releases certain chemical substances in response to acetylcholine. These 
substances are divided into two types according to the functions they perform (Wong et 
al. 2010). Endothelium-derived relaxing factors (EDRFs) including nitric oxide (NO), 
prostacyclin (PGI2) and endothelium-derived hyperpolarizing factors (EDHFs). All of 
them reduce the vascular tone. Opposite to the beneficial EDRFs endothelium also 
produces a vasoconstrictors substance called as endothelial-derived constrictors factors 
(EDCFs). Prostaglandin H2, thromboxane A2 (TXA2), leukotrienes, endothelin, and 
superoxide anions are included in this category (Vanhoutte, 2009). A critical balance is 
required between EDRFs and EDCFs in order to maintain the vascular health and 
function.  Hypertension  and  diabetes  tend  to disturb this  balance via  either increasing 
or decreasing the production of one or both (Vanhoutte et al. 2009). Hyperglycemia 
associated with diabetes modifies the endothelial function through a numbers of complex 
mechanisms including oxidative stress (Laight et al. 2000), glycation of protein and lipids 
(Vlassara et al. 1992), and activation of protein kinase C (Hink et al. 2001). Similarly, the 
endothelial dependent vasodilatation is impaired in different animal models of 
hypertension including spontaneous hypertensive rats and renovascular hypertension 
(Quaschning et al. 2006). ROS formation can be a direct consequence of hyperglycemia.  
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Hyperglycemia induced endothelial cell mitochondrial overproduction of superoxide is 
involved in the pathogenesis of diabetes related complications.  It has  been  proven  that  
the inhibition of hyperglycemia induced overproduction of superoxide by manganese 
superoxide dismutase completely prevents advanced glycation end-product (AGE) 
formation,  protein  kinasae  C  activation  (PKC)  and  the  hexosamine  pathway  in 
endothelial cells (Brownlee, 2001, Nishikawa et al. 2000). Chronic hyperglycemia 
enhances the  local  activity  of  renin-angiotensin-aldosterone system  (Nickenig et al. 
1998), which  leads  to  development of  wall  hypertrophy  and  fibrosis. Hyperglycemia 
can induce superoxide and lower SOD activity leading to impaired endothelium-
dependent vasodilatation in diabetes (Du et al. 2003). Hyperglycemia is thought to 
increase the production of Ang II in various tissues, including blood vessel wall, kidney 
and heart. Ang II stimulates NAD(P)H oxidase via the AT1 receptor, leading to an 
increase in the tissue formation of reactive oxygen species (O2, OH and H2O2). Reactive 
oxygen species induce endothelial dysfunction reducing bioavailability of nitric oxide. 
Endothelial dysfunction leads to the release of endothelin and catecholamines that induce 
vasoconstriction (Giacchetti et al. 2005).  
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Figure1.4: Schematic representation of the involvement of oxidative stress induced 
by diabetes and the development of diabetic complications 
(Adapted from Giacchetti et al. 2005) 
PAI-1: plasminogen activator inhibitor-1, VCAM: vascular cell adhesion molecule,  
ICAM: intercellular adhesion molecule  
 
 
